The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
 
Doris K. Hansen
Honoraria - OncLive
 
Surbhi Sidana
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Janssen; Magenta Therapeutics; Oncopeptides; Sanofi
Research Funding - Allogene Therapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Magenta Therapeutics (Inst)
 
Lauren Peres
No Relationships to Disclose
 
Leyla Shune
No Relationships to Disclose
 
Douglas W. Sborov
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Legend Biotech; Sanofi; Skyline Diagnostics
 
Hamza Hashmi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Janssen; Sanofi
 
Mehmet H. Kocoglu
No Relationships to Disclose
 
Shebli Atrash
Honoraria - Janssen
Speakers' Bureau - Celgene; Janssen
Research Funding - Amgen; Celgene/Bristol-Myers Squibb (Inst); GlaxoSmithKline; Janssen Oncology (Inst); Karyopharm Therapeutics
 
Gary Simmons
Consulting or Advisory Role - Jazz Pharmaceuticals
Speakers' Bureau - Kite/Gilead
 
Nilesh Kalariya
No Relationships to Disclose
 
Christopher J. Ferreri
Stock and Other Ownership Interests - Affimed Therapeutics
Consulting or Advisory Role - Sanofi
 
Aimaz Afrough
No Relationships to Disclose
 
Ankit J. Kansagra
Consulting or Advisory Role - Alnylam; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Oncopeptides; Pfizer; Pharmacyclics; Sanofi; Takeda
 
Peter M. Voorhees
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Secura Bio
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst); Janssen (Inst); TeneoBio (Inst)
Travel, Accommodations, Expenses - Sanofi
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline
 
Melissa Alsina
Honoraria - Janssen
Consulting or Advisory Role - BMS; Janssen Oncology
Speakers' Bureau - Janssen Oncology
 
Joseph McGuirk
Honoraria - AlloVir; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Consulting or Advisory Role - Allovir; EcoR1 Capital; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Frederick L. Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Celgene; Cellular Biomedicine Group; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Novartis; Sana Biotechnology; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Krina K. Patel
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Pfizer
Research Funding - Abbvie/Genentech; Allogene Therapeutics; Celgene/Bristol-Myers Squibb; Cellectis; Janssen; Nektar; poseida therapeutics; Precision Biosciences; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb